Myriad, Gene and UnitedHealthcare

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental health medications are likely to work with an individual patient.
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its engagement with UnitedHealthcare and its initial views on the potential financial ramifications to the company of this policy change.
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad weakness due to UnitedHealth coverage update, says Stephens
Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm blames on an announcement from UnitedHealth (UNH) stating that starting Jan. 1,
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to
How are Americans feeling before Election Day?
Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...
Nasdaq4d
Piper says Myriad appears to be trading down on GeneSight coverage change
Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...
EurekAlert!1y
The GeneSight Test (IMAGE)
With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.
Learning To Achieve Wellness Earns 2024 Best Of Florida Honorable Mention For Holistic Care
BRANDON, FL, UNITED STATES, November 3, 2024 /EINPresswire / -- Learning to Achieve Wellness has carved out a unique space in the world of mental < ...
Nasdaq4d
UnitedHealth update ‘not the end’ for Myriad’s GeneSight, says Raymond James
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...
Wells Fargo Keeps Their Buy Rating on UnitedHealth (UNH)
Wells Fargo analyst Steve Baxter maintained a Buy rating on UnitedHealth (UNH – Research Report) yesterday and set a price target of ...
PBS1d
The Latest
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.